Clinical Trial Update: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder [Phase 2]

View source ↗

Summary

RAP-219 is being studied in a Phase 2 trial to assess its efficacy and safety in adults with Bipolar I Disorder, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• RAP-219

Snippet

Sponsor: Rapport Therapeutics Inc. | Conditions: Bipolar 1 Disorder | Phase 2 | Status: RECRUITING